NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $2.23 billion. The enterprise value is $2.53 billion.
| Market Cap | 2.23B |
| Enterprise Value | 2.53B |
Important Dates
The last earnings date was Tuesday, July 28, 2026, after market close.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 128.48 million shares outstanding. The number of shares has increased by 1.26% in one year.
| Current Share Class | 128.48M |
| Shares Outstanding | 128.48M |
| Shares Change (YoY) | +1.26% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 106.86% |
| Float | 117.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 62.53 |
| PS Ratio | 2.91 |
| Forward PS | 2.64 |
| PB Ratio | 2.83 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 101.21 |
| PEG Ratio | 1.24 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.31 |
| EV / EBITDA | 104.19 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.60, with a Debt / Equity ratio of 0.57.
| Current Ratio | 3.60 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 13.68 |
| Debt / FCF | n/a |
| Interest Coverage | -16.06 |
Financial Efficiency
Return on equity (ROE) is -6.33% and return on invested capital (ROIC) is -3.80%.
| Return on Equity (ROE) | -6.33% |
| Return on Assets (ROA) | -1.89% |
| Return on Invested Capital (ROIC) | -3.80% |
| Return on Capital Employed (ROCE) | -3.33% |
| Weighted Average Cost of Capital (WACC) | 11.54% |
| Revenue Per Employee | $306,518 |
| Profits Per Employee | -$20,751 |
| Employee Count | 2,500 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 14.02 |
Taxes
| Income Tax | -2.67M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +169.30% in the last 52 weeks. The beta is 1.73, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.73 |
| 52-Week Price Change | +169.30% |
| 50-Day Moving Average | 14.76 |
| 200-Day Moving Average | 11.40 |
| Relative Strength Index (RSI) | 64.59 |
| Average Volume (20 Days) | 1,932,703 |
Short Selling Information
The latest short interest is 15.42 million, so 12.00% of the outstanding shares have been sold short.
| Short Interest | 15.42M |
| Short Previous Month | 13.76M |
| Short % of Shares Out | 12.00% |
| Short % of Float | 13.18% |
| Short Ratio (days to cover) | 4.93 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $766.30 million and -$51.88 million in losses. Loss per share was -$0.40.
| Revenue | 766.30M |
| Gross Profit | 336.53M |
| Operating Income | -41.45M |
| Pretax Income | -54.55M |
| Net Income | -51.88M |
| EBITDA | 24.33M |
| EBIT | -41.45M |
| Loss Per Share | -$0.40 |
Balance Sheet
The company has $145.54 million in cash and $448.37 million in debt, with a net cash position of -$302.83 million or -$2.36 per share.
| Cash & Cash Equivalents | 145.54M |
| Total Debt | 448.37M |
| Net Cash | -302.83M |
| Net Cash Per Share | -$2.36 |
| Equity (Book Value) | 785.73M |
| Book Value Per Share | 6.14 |
| Working Capital | 275.60M |
Cash Flow
In the last 12 months, operating cash flow was $22.05 million and capital expenditures -$29.40 million, giving a free cash flow of -$7.36 million.
| Operating Cash Flow | 22.05M |
| Capital Expenditures | -29.40M |
| Depreciation & Amortization | 65.77M |
| Net Borrowing | 41.24M |
| Free Cash Flow | -7.36M |
| FCF Per Share | -$0.06 |
Margins
Gross margin is 43.92%, with operating and profit margins of -5.41% and -6.77%.
| Gross Margin | 43.92% |
| Operating Margin | -5.41% |
| Pretax Margin | -7.12% |
| Profit Margin | -6.77% |
| EBITDA Margin | 3.17% |
| EBIT Margin | -5.41% |
| FCF Margin | n/a |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.26% |
| Shareholder Yield | -1.26% |
| Earnings Yield | -2.32% |
| FCF Yield | -0.33% |
Analyst Forecast
The average price target for NeoGenomics is $19.72, which is 13.53% higher than the current price. The consensus rating is "Buy".
| Price Target | $19.72 |
| Price Target Difference | 13.53% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (3Y) | 9.93% |
| EPS Growth Forecast (3Y) | 57.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.55 |
| Piotroski F-Score | 4 |